| My Account | Sitemap | Subscribe | Contact Us | Help |
Richard K. Bernstein, MD, discusses 19 proven ways to take care of your feet and avoid diabetes-related complications
Scott Brown writes about Denver Broncos quarterback Jay Cutler's life since his recent type 1 diagnosis
Justine Lorelle Blanchard looks at a chilling development among type 1 teens: skipping insulin shots and purging food as a way to achieve rapid weight loss
Beth Morrow follows up on an article we published in May about teens' problems — occasionally fatal — with insulin pumps
Diabetes Health Digital Advantage™, the free, online version of Diabetes Health magazine, virtually identical to the bi-monthly Diabetes Health print magazine, has many additional useful features.
While the pages turn in a similar fashion to a magazine's, direct hot links lead to research articles, products and advertiser sites.
Access to the amazing Diabetes Health Digital Advantage™ is through any web browser, so you can read the current issue of Diabetes Health magazine online wherever you are!
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Related Medications Threads on Diabetes Health Forums
Januvia, also known as sitagliptin phosphate, is a DPP-IV inhibitor. It prevents, or inhibits, DPP-IV from inactivating GLP-1. GLP-1 is a naturally produced hormone that increases insulin secretion in response to food.
1 comment - Nov 20, 2007 -
New Type 2 Drugs Januvia and Byetta Offer Big Benefits
The 21st century may be remembered as the time when diabetes became a worldwide epidemic. However, it may also be known as the time when the disease was cured.
5 comments - May 2, 2007 -
Press Release - JANUVIA™ Approved in the European Union for the Treatment of Type 2 Diabetes
Whitehouse Station, N.J., March 26, 2007 – JANUVIA™ (sitagliptin1), Merck & Co., Inc.'s once-a-day oral treatment for patients with type 2 diabetes, has been granted a license from the European Commission. JANUVIA now becomes the first and only medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood sugar when it is elevated, to be adopted by the European Commission.
0 comments - Apr 18, 2007 -
By October of this year, Merck & Co., Inc., expects the FDA to rule on its novel type 2 drug Januvia (sitagliptin phosphate). On February 15, 2006, the FDA accepted Merck’s New Drug Application (NDA) for Januvia for standard review.
0 comments - May 1, 2006 -
Not Yet Rated